Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4281 trials
Conditions Advanced Breast Cancer
Phase PHASE1
Enrollment 240
Locations 45 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This is a first-in-human study of MEN2312, a lysine acetyltransferase 6 (KAT6) inhibitor, in adult participants with advanced breast cancer.

Design

Study type: Interventional Phases: Phase1 Allocation: Randomized Intervention model: Sequential Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: MEN2312 — MEN2312 administered as oral tablets.
  • Drug: Elacestrant — Elacestrant administered as oral tablets.

Primary Outcomes

  • Number of Participants Experiencing Dose-limiting Toxicity When Administered MEN2312 (Baseline through Day 28)
  • Recommended Phase 2 Dose (RP2D) of MEN2312 (Baseline through Month 6)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1
Status: Recruiting
Start Date: 2024-10-25
Completion: 2029-10-23
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 240 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Stemline Therapeutics, Inc.
Contact Information
Study Contact:
Stemline Trials
1-877-332-7961
clinicaltrials@menarinistemline.com
Joseph Beck, MD
Highlands Oncology Group
Hope Rugo
City of Hope
Interventions
  • Drug: MEN2312 — MEN2312 administered as oral tablets.
  • Drug: Elacestrant — Elacestrant administered as oral tablets.
Study Locations (45 sites)
Highlands Oncology Group, Springdale, Arkansas 72703 United States
City of Hope, Duarte, California 31010 United States
UC San Diego Moores Cancer Center, La Jolla, California 92093-0698 United States
Stanford Cancer Center, Palo Alto, California 94304 United States
UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California 94158 United States
UCLA Hematology Oncology - Parkside, Santa Monica, California 90404 United States
Yale Comprehensive Cancer Center, New Haven, Connecticut 06511 United States
Advent Health Orlando, Altamonte Springs, Florida 32701 United States
Sarah Cannon Research Institute at Florida Cancer Specialists, Orlando, Florida 32827 United States
Florida Cancer Specialists & Research Institute (FCS) - Sarasota, Sarasota, Florida 34232 United States
Eligibility Criteria
Key Inclusion Criteria: * Participant has advanced (locoregionally recurrent or metastatic) breast cancer not amenable to curative therapy. * Presence of genetic alterations in PIK3CA/AKT1/PTEN in participants' tumor tissue. * Participant must have received at least 1 prior line of endocrine therapy for advanced/metastatic disease or participant who has radiological evidence of breast cancer recurrence or progression during or within 12 months from the end of adjuvant treatment with endocrine therapy, as these participants are considered as first-line relapsed participants. * Progression on previous cyclin-dependent kinase 4 and 6 inhibitor treatment in combination with fulvestrant or aromatase inhibitor is required. Key Exclusion Criteria: * Active or newly diagnosed central nervous system metastases. * Participants with advanced, symptomatic visceral spread, who are at risk of life-threatening complications in the short term, including massive uncontrolled effusions (peritoneal, pleural, pericardial), pulmonary lymphangitis, or liver involvement \>50%. * Participants with any toxicities related to prior radiation therapy that have not resolved to baseline or to National Cancer Institute Common Terminology Criteria for Adverse Events v5.0 Grade ≤1, except alopecia and peripheral sensory neuropathy (Grade ≤2). Note: Other inclusion/exclusion criteria may apply.
Conditions Thyroid Nodule
Phase Not Applicable
Enrollment 500
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this observational research is to evaluate and compare the health-related quality of life and emotional well-being of patients with thyroid nodules before and after treatment. This is a data collection study by allowing investigators to access information generated before and after treatment.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Procedure: thermal ablation — thermal ablation including microwave ablation, radiofrequency ablation of thyroid nodules
  • Procedure: thyroidectomy — surgical resection of thyroid nodules

Primary Outcomes

  • The Thyroid Cancer-Specific Quality of Life Questionnaire to assess the thyroid-specific quality of life (before treatment and 1month, 6months, and 12 months after treatment)
  • the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire to assess the general quality of life (before treatment and 1month, 6months, and 12 months after treatment)
  • Hospital Anxiety and Depression Scale to assess the emotional status (before treatment and 1month, 6months, and 12 months after treatment)
  • The functional assessment of chronic illness therapy-spiritual well-being questionnaire to assess spiritual well-being (before treatment and 1month, 6months, and 12 months after treatment)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2022-08-01
Completion: 2027-12
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: true
Enrollment: 500 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Ming-an Yu
Principal Investigators:
  • ming'an yu, MD (STUDY_CHAIR) - China-JapanFriendship Hospital
Contact Information
Study Contact:
ming'an yu, MD
84205756
yma301@163.com
yan li
8420576
497059493@QQ.COM
ming'an yu, MD
84205756
yma301@163.com
China-Japan Frienship Hospital
Interventions
  • Procedure: thermal ablation — thermal ablation including microwave ablation, radiofrequency ablation of thyroid nodules
  • Procedure: thyroidectomy — surgical resection of thyroid nodules
Study Locations (1 sites)
China-Japan Frienship Hospital, Beijing, Beijing Municipality 100029 China
Eligibility Criteria
Inclusion Criteria: * Clinical diagnosis of benign thyroid nodules or papillary thyroid carcinoma ; * underwent microwave ablation or thyroidectomy; * ability to understand and cooperate with the survey Exclusion Criteria: * serious primary diseases in the liver, kidney, hematopoietic, or endocrine systems; * a history of mental illness, personality disorders, cognitive impairments, or organic brain disease
Conditions Diabetes Mellitus, Type 2, Obesity
Phase NA
Enrollment 30
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Surgery is one of the management options for type 2 diabetes in patients with moderate obesity. This is a recent option because it has been part of the recommendations since October 2022. The possible surgical techniques are the same as those for bariatric surgery: * Sleeve, * Bypass, * Gastric band, but the main goal is not weight loss, it is remission of type 2 diabetes. It is called metabolic surgery. The ring technique (gastroplasty) is practiced less and less in France because it is less effective in weight loss and is responsible for major discomfort. Currently, metabolic surgery is one of the recommendations but no study has compared the effectiveness of the techniques with each other. One or other of the techniques can be chosen according to the preferences of the surgeon, the patient, the center, etc. but this choice is not made objectively, in the absence of comparative data. This study would like to follow up on patients for whom metabolic surgery has been proposed by the doctor,. If the surgery is accepted, this study would like to improve knowledge of the effectiveness of the different techniques, and thus demonstrate which metabolic surgery technique is preferred in terms of effectiveness and safety.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Procedure: metabolic surgery with SLEEVE technique — metabolic surgery with SLEEVE technique
  • Procedure: metabolic surgery with BY-PASS technique — metabolic surgery with BY-PASS technique

Primary Outcomes

  • T2DM remission rate (1 year after surgery)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-07-03
Completion: 2032-12-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 30 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Médipôle Lyon-Villeurbanne
Contact Information
Study Contact:
laetitia paradisi, Dr
0033481655296
l.paradisi-prieur@resamut.fr
laetitia paradisi
0033481655296
Medipole Lyon Villeurbanne
Interventions
  • Procedure: metabolic surgery with SLEEVE technique — metabolic surgery with SLEEVE technique
  • Procedure: metabolic surgery with BY-PASS technique — metabolic surgery with BY-PASS technique
Study Locations (1 sites)
Medipole Lyon Villeurbanne, Villeurbanne, 69100 France
Eligibility Criteria
Inclusion Criteria: * adult patient and ≤ 65 years old * T2D patient, with individualized glycemic objectives not achieved, despite medical care, in particular diabetological and nutritional, also including adapted physical activity, well conducted according to current good practice recommendations, for at least twelve months * BMI between 30 and 34.9 kg/m² * patient well informed beforehand about metabolic surgery and the study * multidisciplinary evaluation (including a diabetologist) and decision on medical treatment by CM (date prior to inclusion) * medical assessment of an acceptable surgical risk * patient affiliated to or beneficiary of a social security system * patient having freely signed the written informed consent Exclusion Criteria: * severe cognitive or mental disorders * severe and unstabilized eating behavior disorders * dependence on alcohol and licit and illicit psychoactive substances * illnesses endangering life in the short and medium term * contraindications to general anesthesia * absence of identified prior medical care and foreseeable inability of the patient to participate in lifelong medical monitoring * history of bariatric surgery * pregnant or breastfeeding woman, or having a very long-term pregnancy plan short term (\< 2 years) * adult patient under guardianship or curatorship * patient deprived of liberty or under judicial decision
Conditions Preeclampsia, Gut Dysbiosis
Phase NA
Enrollment 150
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Preeclampsia (PE) is a complication during pregnancy characterized by hypertension, organ damage, and inflammation, without an effective treatment. The underlying mechanisms causing the disease also remain partly unknown. In this double-blind placebo-controlled study, the effects of probiotic dietary supplement GutMagnific during pregnancy will be assessed in pregnancies with a high risk of PE as well as low risk. The hypothesis is that probiotic dietary supplement GutMagnific can prevent or reduce the inflammatory response and clinical manifestations associated with PE through counteracting imbalances in the oral and gut microbiome composition.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Prevention Masking/blinding: Quadruple

Interventions / Regimen

  • Dietary Supplement: GutMagnific — Participants will take one stick/10\^9 CFU of probiotic dietary supplement GutMagnific per day from gestational week 12 until gestational week 37
  • Dietary Supplement: Placebo — Participants will take one stick/placebo per day from gestational week 12 until partus.

Primary Outcomes

  • Changes in oral and gut microbiota composition (Around gestational week 12 (baseline), 28, 37, and 6-8 weeks postpartum. In the event of a participant developing PE, samples will be taken at PE diagnosis as well.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-12-10
Completion: 2027-12
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 150 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Region Skane
Collaborators: ImmuneBiotech Medical Sweden AB
Contact Information
Study Contact:
Stefan R Hansson, Professor
+46 70 6024476
stefan.hansson@med.lu.se
Stefan Hansson
+46706024476
stefan.hansson@med.lu.se
Region Skåne
Interventions
  • Dietary Supplement: GutMagnific — Participants will take one stick/10\^9 CFU of probiotic dietary supplement GutMagnific per day from gestational week 12 until gestational week 37
  • Dietary Supplement: Placebo — Participants will take one stick/placebo per day from gestational week 12 until partus.
Study Locations (1 sites)
Region Skåne, Lund, 221 85 Sweden
Eligibility Criteria
Inclusion Criteria: * Pregnant women ≥ 18 years old * High risk of PE (≥ 1 high-risk factor, or ≥3 moderate risk factors according to the Swedish Society of Obstetrics and Gynecology (SFOG) 2019 guidelines); or low risk of PE (no high-risk factors, or \<3 moderate risk factors): * High risk factors are: * Auto-immune diseases such as SLE or anti-phospholipid syndrome * Previous preeclampsia or eclampsia * Previous hypertension of pregnancy with preterm birth before gestational week 34, growth restriction, intrauterine fetal death or ablatio * Type 1 or 2 diabetes * Duplex (or triplex) pregnancy * Kidney disease * Chronic hypertension * IVF with egg donation * Moderate risk factors are: * Nulliparity * Heredity for preeclampsia (at least one of mother, maternal grandmother, or sister) * BMI\>30 * Age\>40 * Pregnancy interval \>10 years * Systolic blood pressure \>130 mmHg or diastolic blood pressure \> 80 mmHg at admission in antenatal maternity care * African descent * Verified obstructive sleep apnea * Ability to give written informed consent Exclusion Criteria: * Enrollment in another clinical study * Use of other probiotic supplements in the last 2 weeks before baseline, or during the course of the study * Use of antibiotics in the last 6 weeks * Current treatment with metformin, progesterone, or regular medical treatment which may impact study aim (e.g. laxatives) * Immunosuppression * Diabetes mellitus (type I and type II) * Inflammatory bowel disease * Celiac disease * Bad obstetric history * Other serious conditions that might affect gut flora or capability of the subject to participate * Language difficulties or difficulties understanding informed consent
Conditions Diabetes Mellitus Type 2
Phase NA
Enrollment 150
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Community-based health coaching interventions play a vital role in complementing the traditional chronic disease management model for type 2 diabetes patients. Compared to conventional approaches that often focus on periodic clinical visits, community-based coaching could provide continuous, personalised support within patients in everyday environments. Health coaches work directly with patients to set realistic goals, develop individualised action plans, and provide ongoing motivation and accountability. This personalised attention helps to improve self-management skills, such as medication adherence, dietary choices, and physical activity, which are crucial for chronic disease management and preventing complications. Our mobile health app, EMPOWER+ has multiple logging features, gamified elements to help users set goals and provide rewards, educational resources, and personalised nudges generated based on real users; inputs and predictive modeling. It has demonstrated some preliminary effectiveness and acceptability within the clinical settings. This trial aims to assess its effectiveness, adoption, and sustainability in the less-controlled community settings, preparing for its large implementation in the future.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Health Services Research Masking/blinding: None

Interventions / Regimen

  • Behavioral: App-based diabetes management and community-based health coaching — All participants will use the EMPOWER+ app and a Fitbit wearable. They will also received community-based health coaching and/or other prescribed structured programmes.

Primary Outcomes

  • HbA1c (6 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-01-06
Completion: 2026-06-30
Eligibility
Age: 21 Years and older
Sex: ALL
Volunteers: false
Enrollment: 150 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Singapore General Hospital
Contact Information
Study Contact:
Research coordinators
6562223222
empower@singhealth.com.sg
Lian Leng Low
91051097
low.lian.leng@singhealth.com.sg
Singapore General Hospital
Research coordinators
6562223222
empower@singhealth.com.sg
Singapore General Hospital
Interventions
  • Behavioral: App-based diabetes management and community-based health coaching — All participants will use the EMPOWER+ app and a Fitbit wearable. They will also received community-based health coaching and/or other prescribed structured programmes.
Study Locations (2 sites)
Singapore General Hospital, Singapore, Singapore
Singapore General Hospital, Singapore, Singapore
Eligibility Criteria
Inclusion Criteria: * Aged 21 years and above * Having been diagnosed with type 2 diabetes mellitus * Having most recent HbA1c ≥ 6.5% * Physically able to exercise * Able to read, write, and converse in English * Able to comply with study procedures Exclusion Criteria: * Requiring assistance with basic activities of daily living (BADL) * Have planned major operation or surgical procedure within 6 months from the time of recruitment * Current pregnant or lactating
Conditions Major Depressive Disorder
Phase PHASE4
Enrollment 75
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this clinical trial is to learn how hormonal changes over the menstrual cycle affect mood symptoms in reproductive-aged women with depression that worsens during the premenstrual period. The main questions it aims to answer are: --How do fluctuations in estradiol and progesterone across the menstrual cycle affect the ability to experience pleasure and the neural sensitivity to reward in hormone-sensitive, depressed women? And consequently, how does stabilizing the luteal phase decline in estrogen and progesterone (using estradiol patches and progesterone pills) affect these changes? Participants will: * Receive hormones followed by placebo, or vice versa, for a total of four weeks across three menstrual cycles * Complete daily mood ratings * Collect home urine samples for hormone testing * Complete five biobehavioral testing sessions during which neural responses are recorded (via electroencephalography, or EEG) during an acute stress task and computer tasks

Design

Study type: Interventional Phases: Phase4 Allocation: Randomized Intervention model: Crossover Primary purpose: Other Masking/blinding: Triple

Interventions / Regimen

  • Drug: Transdermal estradiol — 0.1 mg/day delivered via weekly patch
  • Drug: Progesterone — 100 mg twice daily (200 mg/day total) administered via oral capsule
  • Drug: Transdermal placebo patch — Once weekly via transdermal patch
  • Drug: placebo capsule — Twice daily via oral capsule

Primary Outcomes

  • Dimensional Anhedonia Rating Scale (Luteal Phase Stabilized vs Luteal Phase Unstabilized Hormones vs Follicular Phase) (3 menstrual cycles (each cycle approximately 28 days in duration))
  • Reward Positivity (Luteal Phase Stabilized vs Luteal Phase Unstabilized Hormones vs Follicular Phase) (Over the course of 2 menstrual cycles (~28 days each), EEG will be collected four times on four separate days: twice during the late luteal phase (11-14 days following ovulation), and twice during the mid follicular phase (23-25 days following ovulation))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE4
Status: Recruiting
Start Date: 2024-09-02
Completion: 2028-06-01
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 75 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of North Carolina, Chapel Hill
Collaborators: National Institute of Mental Health (NIMH)
Principal Investigators:
  • Chris Sikes-Keilp, MD (PRINCIPAL_INVESTIGATOR) - University of North Carolina, Chapel Hill
Contact Information
Study Contact:
Study Coordinator
(919) 445-6814
pearstudy@unc.edu
Study Coordinator
(919) 445-6814
pearstudy@unc.edu
University of North Carolina, Chapel Hill
Interventions
  • Drug: Transdermal estradiol — 0.1 mg/day delivered via weekly patch
  • Drug: Progesterone — 100 mg twice daily (200 mg/day total) administered via oral capsule
  • Drug: Transdermal placebo patch — Once weekly via transdermal patch
  • Drug: placebo capsule — Twice daily via oral capsule
Study Locations (1 sites)
University of North Carolina, Chapel Hill, Chapel Hill, North Carolina 27707 United States
Eligibility Criteria
Inclusion Criteria: * Biologically female and between the ages of 18-45 years (45 set as upper limit to avoid endocrine changes associated with perimenopause). * Self-reported regular menstrual cycles between 25 and 35 days. * A previous diagnosis of major depressive disorder, with self-reported premenstrual worsening of symptoms. * If the woman has children, she must be at least 1 year postpartum. * English-speaking Exclusion Criteria: * Pregnant, breastfeeding, or trying to become pregnant. Pregnancy status will be confirmed using a urine pregnancy test at the enrollment visit and again at the first visit of the second condition. Women will be instructed to use a barrier method of birth control during the study. * Taking any form of exogenous hormones or IUD, and must have ended previous use of hormonal preparations at least one month prior to the study. Women who were previously taking oral contraceptives or other hormonal medications must have one normal menstrual cycle (menstrual period) prior to enrollment in the study. * BMI less than 18 or greater than 29. * A personal history of any chronic medical condition that could confound the experimental protocol, including but not limited to metabolic or autoimmune disease, epilepsy, endometriosis, cancer, diabetes, cardiovascular, gastrointestinal, hepatic, renal, pulmonary disease, migraine with aura, hypertension, Parkinson's disease, chronic pain, and thromboembolic events. * A family history indicative of increased risk of breast cancer or thromboembolic disorders. * Current cigarette smoking. * A history of mania, psychosis, or substance use disorder. * Any recent history (last 12 months) of active suicidal ideation, or suicide attempt within the last 5 years.
Conditions Diabetes Mellitus, Type 2, Cardiovascula...
Phase NA
Enrollment 2714
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this pragmatic trial is to provide Real World Evidence (RWE) on the impact of the result of a polygenic risk prediction test of cardiorenal complications of T2D, so that more patients at high risk of these complications achieve over an 18 months period, recommended therapeutic targets. This will be demonstrated as a significant improvement in a composite value including HbA1c or systolic blood pressure (SBP) or albuminuria (UACR), or glomerular filtration rate (GFR) lowering. Researchers will compare the recommended therapeutic targets of uninformed and informed patients to see if the knowledge of the risk by the patients and their treating physicians improves achievement of these targets. Participants will: Have a saliva sampling to determine the genetic risk. Visit the clinic once every 3 months for checkups and tests Answer two questionnaires on quality of life.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Prevention Masking/blinding: Double

Interventions / Regimen

  • Device: Polygenic Risk Score — The Polygenic Risk Score (PRS) is a Class II software as a medical device (SaMD) that estimates a person's level of risk of developing a disease or associated complications before clinical signs appear. The device uses the genomic profile of the person in combination with some clinical data (i.e., age, sex, age of onset of diabetes) to compute this risk. This device further provides recommendations for personalized management of T2D for patients based on their risk score.

Primary Outcomes

  • Composite endpoint consisting of HbA1c, SBP, albuminuria or GFR (Visit to visit up to 18 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-08-23
Completion: 2028-08-23
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 2714 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Optithera
Collaborators: Genome Quebec, Genome Canada, ELNA Medical
Principal Investigators:
  • Pavel Hamet, MD, PhD (PRINCIPAL_INVESTIGATOR) - CHUM
Contact Information
Study Contact:
Marie-Renée Guertin, il,cra
514-249-4209
marie-renee.guertin.chum@ssss.gouv.qc.ca
Johanne Tremblay, PhD
514-890-8247
johanne@optithera.onmicrosoft.com
Marie-Renée Guertin, Il, CRA
1-514-249-4209
marie.renee.guertin.chum@ssss.gouv.qc.ca
CHUM
Interventions
  • Device: Polygenic Risk Score — The Polygenic Risk Score (PRS) is a Class II software as a medical device (SaMD) that estimates a person's level of risk of developing a disease or associated complications before clinical signs appear. The device uses the genomic profile of the person in combination with some clinical data (i.e., age, sex, age of onset of diabetes) to compute this risk. This device further provides recommendations for personalized management of T2D for patients based on their risk score.
Study Locations (2 sites)
CHUM, Montreal, Quebec H2X 0A9 Canada
ELNA Medical, Montreal, Quebec H3S 1Z5 Canada
Eligibility Criteria
Inclusion Criteria: * Adult patients with T2D of both sexes regardless of ethnicity, level of diabetes control and presence of complications. * Able to visit the study site 7 times * Able and willing to provide informed consent to the clinical and PRS parts of the study. Exclusion Criteria: * Any condition that may impact participation in a real-world study according to the treating physician. * People with a high frailty index as no benefit of therapeutic intensification has been demonstrated in these diabetic patients. * People who refuse to be informed of their cardiorenal risk score.
Conditions Type 2 Diabetes Treated With Insulin
Phase NA
Enrollment 224
Locations 12 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The main objective of this study is to determine the efficacy, safety and utility of fully closed-loop glucose control in the home setting in adults with type 2 diabetes (T2D). This study builds on previous and on-going studies of closed-loop systems that have been performed in Cambridge in adults with type 2 diabetes in the inpatient and in the home setting and in children and adults with type 1 diabetes. This is an open-label, multi-national, multi-centre, randomised, single-period parallel study, involving a run-in period followed by a 26-week intervention period during which glucose levels will be controlled either by a fully closed-loop system or by participants usual insulin therapy with continuous glucose monitoring. A total of up to 224 adults with type 2 diabetes using insulin will be recruited through outpatient diabetes clinics, primary care centres, social media advertising and other established methods at participating centres. Participants will receive appropriate training in the safe use of the study devices. The primary outcome is the between group difference in HbA1c at 26 weeks. Other key outcomes include the time spent with glucose levels within, above and below the target glucose range (3.9-10.0mmol/L) and mean sensor glucose as recorded by CGM over the 26 weeks. Insulin requirements, body weight, renal and liver function will also be compared. Safety evaluation comprises severe hypoglycaemic episodes, and other adverse and serious adverse events. Human factors outcomes include CGM \& closed-loop usage, questionnaires and semi-structured interviews.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Device: CamAPS HX — The automated closed loop system (CamAPS HX) will consist of: YpsoPump insulin pump Freestyle Libre 3 glucose sensor Smartphone hosting CamAPS HX app with the Cambridge model predictive control algorithm
  • Other: Standard insulin therapy with glucose sensor — Participants usual insulin therapy with Freestyle Libre 3 glucose sensor

Primary Outcomes

  • Glycated haemoglobin (HbA1c) at 26 weeks (at 26 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-12-06
Completion: 2027-07
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 224 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Cambridge
Collaborators: University of Edinburgh, Jaeb Center for Health Research, Swansea University
Principal Investigators:
  • Roman Hovorka (PRINCIPAL_INVESTIGATOR) - University of Cambridge
Contact Information
Study Contact:
Charlotte K Boughton, PhD
+44 (0)1223 769066
cb2000@medschl.cam.ac.uk
Angel Tseung
ftt20@cam.ac.uk
David O'Neal
University of Melbourne
Interventions
  • Device: CamAPS HX — The automated closed loop system (CamAPS HX) will consist of: YpsoPump insulin pump Freestyle Libre 3 glucose sensor Smartphone hosting CamAPS HX app with the Cambridge model predictive control algorithm
  • Other: Standard insulin therapy with glucose sensor — Participants usual insulin therapy with Freestyle Libre 3 glucose sensor
Study Locations (12 sites)
University of Melbourne, Melbourne, Australia
Medical University of Graz, Graz, Austria
Diabetes Centre, Institute of Clinical and Experimental Medicine, Prague, Czechia
CHU de Toulouse, Toulouse, France
Bern University Hospital, Bern, Switzerland
Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom
Royal Derby Hospital, Derby, United Kingdom
Leicester Diabetes Centre, Leicester, United Kingdom
Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom
King's College Hospital, King's College NHS Foundation Trust, London, United Kingdom
Eligibility Criteria
Inclusion Criteria: * Aged 18 years and older * Type 2 diabetes diagnosed for at least 12 months * Established on an SGLT2 inhibitor and/or GLP-1 receptor agonist for at least 3 months, or have been offered these therapies previously. * Treatment with insulin therapy for at least 6 months * HbA1c ≤ 15% (140 mmol/mol) analysis from local laboratory or equivalent * Willing to wear study devices and follow study instructions * Capacity to consent to participate in the study Exclusion Criteria: * Type 1 diabetes * Current use of insulin pump * Current use of any closed-loop system * Any physical/psychological disease or medication(s) likely to interfere with the conduct of the study and interpretation of the study results, as judged by study clinician * Known or suspected allergy against insulin * Medically documented allergy towards the adhesive * Pregnancy, planned pregnancy, or breast feeding * Severe visual impairment * Severe hearing impairment * Medically documented allergy towards the adhesive (glue) of plasters * Serious skin diseases located at places of the body, which potentially are possible to be used for localisation of the glucose sensor * Illicit drugs abuse * Prescription drugs abuse * Alcohol abuse
Conditions Diabetes, Type 2 Diabetes, Type 2 Diabet...
Phase NA
Enrollment 17
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This non-blinded, non-randomized pre-post study will examine the impact of providing CGM sensors free of charge to adult patients of Fair Haven Community Health Care with poorly controlled type 2 diabetes on glycemic control and quality of life.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Supportive Care Masking/blinding: None

Interventions / Regimen

  • Device: Continuous Glucose Monitor (CGM) — The first CGM sensor will be applied as directed during the first visit with a brief training by staff. Participant will be instructed to remove and replace the device every 14 days for the remainder of the 3-month trial period. Participant will also be instructed to scan the sensor three times daily. Compliance may be tracked via remote accessing of the blood glucose log on the online FreeStyle portal. CGM models used will include the Abbott FreeStyle Libre 2 and 3 and Dexcom G5, G6 and G7.

Primary Outcomes

  • Mean Illness Intrusiveness Ratings Scale score (IIRS) (Baseline, 12 weeks, 24 weeks)
  • Mean Hemoglobin A1c concentration (Baseline, 12 weeks, 24 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-11-12
Completion: 2026-06
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 17 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Yale University
Collaborators: Yale Office of Global Health
Principal Investigators:
  • Kasia Lipska, MD MHS (PRINCIPAL_INVESTIGATOR) - Yale University
Contact Information
Study Contact:
Justin A Dower, MD
(973) 901-4431
justin.dower@yale.edu
Anne Camp, MD
(203) 927-6666
a.camp@fhchc.org
Interventions
  • Device: Continuous Glucose Monitor (CGM) — The first CGM sensor will be applied as directed during the first visit with a brief training by staff. Participant will be instructed to remove and replace the device every 14 days for the remainder of the 3-month trial period. Participant will also be instructed to scan the sensor three times daily. Compliance may be tracked via remote accessing of the blood glucose log on the online FreeStyle portal. CGM models used will include the Abbott FreeStyle Libre 2 and 3 and Dexcom G5, G6 and G7.
Study Locations (1 sites)
Fair Haven Community Health Care (FHCHC), New Haven, Connecticut 06520 United States
Eligibility Criteria
Inclusion Criteria: * Provision of signed and dated informed consent form * Stated willingness to comply with all study procedures and availability for the duration of the study * Diagnosed with type 2 diabetes mellitus * A1c greater than or equal to 8.0 within two weeks of the time of enrollment * On insulin for at least one year +/- other antihyperglycemics * Ability and willingness to wear CGM for 14-day periods throughout the trial period * Ability and willingness to comply with provider-directed adjustments to medication regimen * Inability to afford CGM sensors A note on Vulnerable Populations: Many of FHCHC's patients are economically disadvantaged and of minority backgrounds; the clinic's patient base may be considered to constitute a vulnerable population. As such, recruitment and enrollment will be conducted within a vulnerable population. The nature of the study requires this, and the results are intended to directly benefit this population through the potential for improved glycemic control and quality of life. Exclusion Criteria: * Insulin naïve * Diabetic ketoacidosis (DKA) in previous 6 months * End-Stage Renal Disease (ESRD) * Contraindications to CGM use * Active insurance plan that would provide enough of a subsidy for participant to feasibly purchase CGM sensors * Pregnancy
Conditions Breast Cancer Metastatic
Phase PHASE2
Enrollment 40
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Prevention of Sacituzumab Govitecan-related Neutropenia in Patients with metastatic Triple Nagative Breast Cancer who have received at least one, and no more than two, prior standard of care chemotherapy regimens

Design

Study type: Interventional Phases: Phase2 Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Sacituzumab Govitecan with pegfilgrastim — ▪ Sacituzumab Govitecan group \- Sacituzumab Govitecan 10mg/kg IV on CnD1 and D8 + Pegfilgrastim 6mg SC QD on CnD9

Primary Outcomes

  • To evaluate the incidence of grade ≥3 neutropenia (At the end of Cycle 2 (each cycle is 21 days))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2025-07-03
Completion: 2027-12-31
Eligibility
Age: 19 Years and older
Sex: ALL
Volunteers: false
Enrollment: 40 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Yeon Hee Park
Contact Information
Study Contact:
Yeon Hee Park, Ph.D
82-2-3410-3459
yhparkhmo@gmail.com
Yeon Hee Park
Samsung Medical Center
Interventions
  • Drug: Sacituzumab Govitecan with pegfilgrastim — ▪ Sacituzumab Govitecan group \- Sacituzumab Govitecan 10mg/kg IV on CnD1 and D8 + Pegfilgrastim 6mg SC QD on CnD9
Study Locations (1 sites)
Samsung Medical Center, Seoul, 06351 South Korea
Eligibility Criteria
Inclusion Criteria: 1. Signed Informed Consent Form (ICF) prior to participation in any study-related activities. 2. Patients aged ≥19 years at the time of signing ICF. 3. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. 4. Life expectancy of ≥ 12 weeks. 5. Histologically confirmed TNBC per American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) criteria based on local testing on the most recent analyzed biopsy. Triple-negative is defined as \<1% expression for estrogen receptor (ER) and progesterone receptor (PgR) and negative for human epidermal growth factor receptor 2 (HER2) (0-1+ by IHC or 2+ and negative by in situ hybridization \[ISH) test\]. 6. Metastatic disease documented by computerized tomography (CT) scan or magnetic resonance imaging (MRI) that is not amenable to resection with curative intent. 7. Refractory to at least one, and no more than two, prior standard of care chemotherapy regimens for unresectable locally advanced or MBC. PARP inhibitor could have been counted as prior chemotherapy for purposes of study eligibility. 8. All patients must have been previously treated with taxanes regardless of disease stage (adjuvant, neoadjuvant, or advanced), unless contraindicated for a given patient. 9. Measurable or non-measurable, but evaluable disease, as per RECIST v.1.1. Patients with bone-only metastases are also eligible. 10. Brain MRI must be done for patients with suspicion of brain metastases and patient must have stable central nervous system (CNS) disease for at least 4 weeks after local therapy, without neurological symptoms, and off anticonvulsants and steroids (no more than 10mg/day prednisone or its equivalent) for at least 2 weeks before first dose of study treatment. 11. Meet the following organ function requirements: * Hemoglobin ≥ 9 g/dL * ANC ≥ 1500/mm3 * Platelets ≥ 100,000/μL * Bilirubin ≤ 1.5 X IULN or ≤ 3X IULN for patients with documented Gilbert's syndrome * AST and ALT ≤ 2.5 X IULN or ≤ 5 X IULN if known liver metastases * Serum albumin \> 3 g/dL * Creatinine clearance ≥ 60 mL/min or ≥ 30 mL/min as assessed by the Cockcroft-Gault equation * INR/PT and PTT or aPTT ≤ 1.5 X IULN unless patient is currently receiving therapeutic anticoagulant therapy 12. Resolution of all acute AEs of prior anti-cancer therapy to grade 1 as determined by the NCI-CTCAE v.5.0 (except for alopecia or other toxicities not considered a safety risk for the patient at investigator discretion). 13. Male patients and female patients of childbearing potential who engage in heterosexual intercourse must agree to use institution specified method(s) of contraception during treatment with sacituzumab govitecan and for 6months after the last dose. * Required contraception for female of childbearing potential patients using hormonally based method, intrauterine device (IUD), bilateral tubal occlusion, female condom with spermicide should during study period and continue until 6 months after the last dose of latest administered study drug * Required contraception for male patients using abstinence, male condom with spermicide, vasectomy should during study period and continue until 6 months after the last dose of latest administered study drug 14. Patients must have completed all prior cancer treatments at least 2 weeks prior to 1st infusion of study drug including chemotherapy (includes also endocrine treatment), radiotherapy, and major surgery. * Prior anticancer biologic agent must have been completed at least 4 weeks prior to 1st infusion of study drug. Exclusion Criteria: 1. Prior treatment with topoisomerase 1 inhibitors as a free form or as other formulations. 2. Received any prior treatment with a Trop-2-directed ADC. 3. Patients with carcinomatous meningitis. 4. Known hypersensitivity reaction to any investigational or therapeutic compound or their incorporated substances. 5. Patients positive for HIV-1 or -2 with a history of Kaposi sarcoma and/or Multicentric Castleman Disease. 6. Have active hepatitis B virus (HBV) (defined as having a positive hepatitis B surface antigen test) or hepatitis C virus (HCV). In patients with a history of HBV or HCV, patients with detectable viral loads will be excluded. 1. Patients who test positive for hepatitis B surface antigen will be excluded. 2. Patients who test positive for hepatitis B core antibody will require HBV DNA by quantitative polymerase chain reaction (PCR) for confirmation of active disease. Patients with positive hepatitis B core antibody but negative viral load by PCR may be eligible if they are being monitored for potential viral reactivation or are willing to start or maintain antiviral treatment during study conduction (as dictated by their local and institutional standard practice or guidelines). A patient with a history of HBV infection and presence of hepatitis B surface antibody may participate in the study. In this last scenario, viral load (HBV DNA) is not mandated. 3. Patients who test positive for HCV antibody will require HCV RNA by quantitative PCR for confirmation of active disease. Patients with a known history of HCV or a positive HCV antibody test will not require an HCV antibody at screening and will only require HCV RNA by quantitative PCR for confirmation of active disease. 7. Scheduled surgery during the study, other than minor surgery which would not delay study drug (eg, port insertion, tooth extraction, any procedure that requires \< 1-hour general anesthesia. Procedures performed under local or intravenous (IV)/monitored sedation that lasts \< 2 hours are acceptable). 8. Have an active second malignancy. Note: Patients with a history of malignancy that has been completely treated, with no evidence of active cancer for 3 years prior to enrollment, or patients with surgically cured tumors with low risk of recurrence (eg, nonmelanoma skin cancer, histologically confirmed complete excision carcinoma in situ, or similar) are eligible. 9. Known history of clinically significant bleeding, intestinal obstruction, or gastrointestinal perforation within 6 months of study initiation. 10. Active or prior documented inflammatory bowel disease (i.e. Crohn's disease, ulcerative colitis, or a preexisting chronic condition resulting in baseline grade ≥1 diarrhea). 11. Infection requiring antibiotic use within 1 week of 1st infusion of study drug. 12. Other concurrent medical or psychiatric conditions that, in the Investigator's opinion, may be likely to confound study interpretation or prevent completion of study procedures and follow-up examinations. 13. Women who are pregnant or lactating. 14. Concomitant participation in other interventional clinical trial. Note: Patients participating in observational studies are eligible. 15. Any medical condition that, in the investigator's or sponsor's opinion, poses an undue risk to the patient's participation in the study 16. Use of other investigational drugs (drugs not marketed for any indication) within 28 days or 5 half-lives (whichever is longer) of first dose of study drug.
Conditions Type 2 Diabetes, Obesity
Phase NA
Enrollment 15
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Obesity is a multifactorial disease in which excess body fat accumulation increases the risk of other chronic diseases such as type 2 diabetes. The primary cause of obesity is the energy imbalance between calories consumed and expended. A balanced diet is essential for weight control and maintaining a healthy body weight. In this context, the intake of a high saturated fat meal (HSFM) plays a detrimental role, contributing to the development of obesity, type 2 diabetes, cancer, cardiovascular diseases, and exacerbating chronic inflammation. Additionally, it may induce metabolic endotoxemia and modulate profiles of circulating microRNAs. Therefore, due to the harmful health impacts of HSFM, studies on metabolomics and circulating microRNA levels could enhance understanding of the mechanisms of walnuts (Juglans regia) in the prevention and treatment of diseases. The aim of this study is to evaluate whether acute walnut supplementation attenuates the inflammatory response, oxidative stress, glycemic response, and regulates the metabolomic and circulating microRNA responses induced by HSFM in women with obesity and type 2 diabetes. The study will be randomized and crossover, including obese, non-insulin-dependent diabetic women aged over 18, without other comorbidities. In the first phase, participants will arrive at the clinic after a 10-hour fast and will be offered HSFM with or without 30g of walnuts. In the second phase, participants who did not receive walnuts will now receive them along with the HSFM and vice versa. Blood samples will be collected, and serum insulin, glucose, serum biomarkers of inflammation and oxidative stress will be evaluated. TNF-alpha, IL-6, IL-1β, IL-1ra, IL-8, and IL-10 will be measured by ELISA, and MDA by HPLC. Additionally, metabolomic and microRNA analyses will be conducted. Data analysis will be performed using JAMOVI v 2.3.21, with a significance level of 5%.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Crossover Primary purpose: Prevention Masking/blinding: None

Interventions / Regimen

  • Dietary Supplement: Nuts in the first meeting — 30g of walnuts
  • Other: Nuts in the second meeting — 30g of walnuts

Primary Outcomes

  • Oxidative stress assessment (6 weeks)
  • Metabolomic profile assessment (6 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-01-15
Completion: 2025-07-15
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 15 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Raquel Ballarin
Collaborators: Faculdade de Medicina de Botucatu, UNESP, Botucatu, Brasil
Principal Investigators:
  • Marcos M Ferreira, PhD (PRINCIPAL_INVESTIGATOR) - FMB/Unesp
Contact Information
Study Contact:
Raquel S Ballarin, M.D.
5514997864806
raquel.ballarin@unesp.br
Nayane M Vieira, Master
5514996536445
n.vieira@unesp.br
Raquel S Ballarin, M.D.
14997864806
raquel.ballarin@unesp.br
São Paulo State University (UNESP), Medical School, Botucatu
Interventions
  • Dietary Supplement: Nuts in the first meeting — 30g of walnuts
  • Other: Nuts in the second meeting — 30g of walnuts
Study Locations (1 sites)
São Paulo State University (UNESP), Medical School, Botucatu, Botucatu, São Paulo 18.618-970 Brazil
Eligibility Criteria
Inclusion Criteria: * Women over 18 years of age * Diagnosis of obesity (body mass index \[BMI \>30 kg/m²\]) * Diagnosis of non-insulin-dependent type II diabetes Exclusion Criteria: * Use of dietary supplements or corticosteroid use in the last 3 months * Diagnosis of insulin dependent diabetes * Diagnosis of cancer * Diagnosis of heart failure * Diagnosis of kidney diseases * Diagnosis of liver diseases * Diagnosis of lung diseases * Diagnosis ofneurological diseases * Diagnosis of allergy to any component of the high saturated fat meal or walnuts
Conditions Breast Cancer Screening and Diagnosis
Phase NA
Enrollment 2200
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Women at high risk of breast cancer (BC) should undergo annual magnetic resonance imaging (MRI) and digital mammography (DM) from at least ages 35 to 60. While MRI is an expensive and scarce resource, contrast-enhanced mammography (CEM) is a less costly and time-consuming alternative that could be used to screen these women instead of MRI. The Con-TRUST trial aims to randomize 1400 women in 10 centers to test whether CEM can be used instead of MRI+DM for BC detection in high-risk women (\&amp;amp;amp;amp;amp;gt;5% 5-year BC risk). The study will compare efficacy in reducing the incidence of BC in women who tested negative in the first screening and cumulative recall rates over 2 screening rounds. All women will be followed up for 2.5 years. Secondary outcomes include screening performance, safety, and women\&amp;amp;amp;amp;amp;#39;s compliance. The trial results will be integrated with the international literature and proposed for the development of recommendations as part of the adolopment of European guidelines in Italy.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Screening Masking/blinding: Single

Interventions / Regimen

  • Diagnostic Test: Contrast Enhancement Mammography — In the experimental arm women will receive two rounds of CEM surveillance. After 2 years, all women who were randomly assigned to receive either MRI or CEM will undergo the same exit test. This exit test is the standard test used for the surveillance of high-risk non mutated women at each participating center.
  • Diagnostic Test: magnetic resonance imaging (MRI) and digital mammography (DM) — women will receive two rounds of MRI+DM surveillance. After 2 years, all women who were randomly assigned to receive either MRI or CEM will undergo the same exit test. This exit test is the standard test used for the surveillance of high-risk nonmutated women at each participating center.

Primary Outcomes

  • Cumulative incidence of BC (24 months)
  • Cumulative recall rate (24 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-02-01
Completion: 2030-01-07
Eligibility
Age: 35 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 2200 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Azienda USL Reggio Emilia - IRCCS
Collaborators: Istituto Oncologico Veneto IRCCS, Azienda Ospedaliera Universitaria Policlinico "G. Martino", Azienda Ospedaliera Universitaria (AOU) Bari, Azienda Ospedaliera Universitaria Integrata Verona, Fondazione IRCCS Policlinico San Matteo di Pavia, Azienda Ospedaliero-Universitaria di Modena, Azienda USL della Romagna, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Contact Information
Study Contact:
Paolo Giorgi Rossi, PhD, Specialization
+39335499770
paolo.giorgirossi@ausl.re.it
Interventions
  • Diagnostic Test: Contrast Enhancement Mammography — In the experimental arm women will receive two rounds of CEM surveillance. After 2 years, all women who were randomly assigned to receive either MRI or CEM will undergo the same exit test. This exit test is the standard test used for the surveillance of high-risk non mutated women at each participating center.
  • Diagnostic Test: magnetic resonance imaging (MRI) and digital mammography (DM) — women will receive two rounds of MRI+DM surveillance. After 2 years, all women who were randomly assigned to receive either MRI or CEM will undergo the same exit test. This exit test is the standard test used for the surveillance of high-risk nonmutated women at each participating center.
Study Locations (1 sites)
Istituto in tecnologie avanzate e modelli assistenziali in oncologia - AUSL-IRCCS Reggio Emilia, Reggio Emilia, Italy/Reggio Emilia 42122 Italy
Eligibility Criteria
Inclusion Criteria: * Women at high risk of developing breast cancer already in care at participating centers or new referral for early diagnosis programs, aged between 35 and 60 years, with an estimated risk of breast cancer in the next 5 years \>=5%. To estimate the 5-year risk, centers may use one of the following models and criteria: * Tyrer Cuzick IBIS: criterion \>10% at 10 years; * BOADICEA: criterion \>10% at 10 years; * BCSC: criterion \>10% at 10 years (if possible switch to Tyrer-Cuzick if \>=2 relatives with breast or ovarian cancer); * MyPeBS (Mammorisk): woman included at very high risk in the MyPeBS study and who has completed the active follow-up period; * Women with previous chest irradiation for radiotherapy Exclusion Criteria: * \- Previous breast cancer; * Pregnancy; * Bilateral mastectomy; * Psychiatric or other disorders not compatible with compliance with the protocol and follow-up requirements; * Women who do not intend or cannot be followed for at least 2.5 years; * Women are unable to understand the information or to express a truly informed consent or non-consent to participation.